首页> 外文期刊>British Medical Journal >Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study
【24h】

Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study

机译:酶促脱敏治疗季节性变应性鼻炎:双盲随机对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To assess the efficacy of enzyme potentiated desensitisation in the treatment of severe summer hay fever poorly controlled by pharmacotherapy. Design Double blind randomised placebo controlled parallel group study. Setting Hospital in Hampshire. Participants 183 participants aged between 18 and 64 with a history of severe summer hay fever for at least two years; all were skin prick test positive to timothy grass pollen. 90 randomised to active treatment; 93 randomised to placebo. Interventions Active treatment: two injections of enzyme potentiated desensitisation, given between eight and 11 weeks apart, each comprising 200 Fishman units of β glucuronidase, 50 pg 1,3- cyclohexanediol, 50 ng protamine sulphate, and a mixed inhaled allergen extract (pollen mixes for trees, grasses, and weeds; allergenic fungal spores; cat and dog danders; dust and storage mites) in a total volume of 0.05 ml buffered saline. Placebo: two injections of 0.05 ml buffered saline solution. Main outcome measures Proportion of problem-free days; global rhinoconjunctivitis quality of life scores assessed weekly during pollen season. Results The active treatment group and the placebo group did not differ in the proportion of problem-free days, quality of life scores, symptom severity scores, change in quantitative skin prick provocation threshold, or change in conjunctival provocation threshold. No clinically significant adverse reactions occurred. Conclusions Enzyme potentiated desensitisation showed no treatment effect in this study.
机译:目的评估酶促脱敏治疗药物治疗难以控制的严重夏季花粉症的疗效。设计双盲随机安慰剂对照平行组研究。在汉普郡设置医院。参加者183人,年龄在18至64岁之间,有严重的夏季花粉热史,至少两年。所有人对蒂莫西草花粉的皮肤点刺试验均为阳性。 90例随机接受积极治疗; 93随机接受安慰剂。干预措施积极治疗:两次注射增强酶的脱敏酶,间隔8至11周,每次注射均包含200个Fishman单位的β葡萄糖醛酸苷酶,50 pg 1,3-环己二醇,50 ng鱼精蛋白硫酸盐和混合吸入的过敏原提取物(花粉混合物)适用于树木,草和杂草;致敏性真菌孢子;猫和狗皮屑;灰尘和储存螨虫),其缓冲液的总体积为0.05 ml。安慰剂:两次注射0.05 ml缓冲盐溶液。主要成果指标无问题日的比例;在花粉季节每周评估全球鼻结膜炎生活质量评分。结果积极治疗组和安慰剂组在无问题日的比例,生活质量评分,症状严重程度评分,定量皮肤刺痛阈值或结膜刺激阈值方面无差异。没有发生临床上明显的不良反应。结论酶增强的脱敏作用在本研究中未显示治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号